Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Federated Hermes Inc.

Federated Hermes Inc. lifted its position in shares of Insmed Incorporated (NASDAQ:INSM) by 448.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 235,836 shares of the biopharmaceutical company’s stock after acquiring an additional 192,853 shares during the quarter. Federated Hermes Inc.’s holdings in Insmed were worth $16,282,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in INSM. Norges Bank acquired a new position in shares of Insmed during the fourth quarter worth about $126,606,000. Vanguard Group Inc. boosted its holdings in Insmed by 6.3% during the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company’s stock worth $1,257,838,000 after buying an additional 1,075,796 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Insmed by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after buying an additional 273,759 shares in the last quarter. Artisan Partners Limited Partnership boosted its holdings in Insmed by 8.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,126,339 shares of the biopharmaceutical company’s stock worth $215,842,000 after buying an additional 242,242 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in Insmed by 12.9% during the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after buying an additional 214,130 shares in the last quarter.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Morgan Stanley boosted their price objective on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Bank of America boosted their price objective on shares of Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a report on Thursday, March 20th. UBS Group increased their price target on shares of Insmed from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. Guggenheim reiterated a “buy” rating and issued a $101.00 price target on shares of Insmed in a research report on Tuesday, February 25th. Finally, Truist Financial raised their target price on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $94.00.

Insider Activity

In other news, CEO William Lewis sold 18,750 shares of Insmed stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the completion of the transaction, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at approximately $25,742,347.58. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Martina M.D. Flammer sold 6,172 shares of Insmed stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.64, for a total transaction of $392,786.08. Following the completion of the transaction, the insider now directly owns 101,549 shares of the company’s stock, valued at $6,462,578.36. This trade represents a 5.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 514,731 shares of company stock valued at $40,530,912. Company insiders own 4.60% of the company’s stock.

Insmed Price Performance

Shares of INSM stock opened at $67.55 on Thursday. The firm has a market cap of $12.23 billion, a P/E ratio of -12.08 and a beta of 1.07. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91. The firm has a fifty day moving average of $76.71 and a two-hundred day moving average of $73.73.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, research analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.